Immutep Ltd (IMMP) Stock AnalysisIMMPStock AnalysisImmutep Ltd

Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immutep Ltd (IMMP) is currently priced at $0.381, significantly below its historical high of $3.53, suggesting potential upside. However, the RSI is at 40.446, indicating a lack of momentum, and the stock has suffered an 87.08% decline year-to-date. The recent FDA Orphan Drug Designation for Eftilagimod Alfa is a positive catalyst, but the stock's volatility and recent downgrades from analysts present risks. The main risk is the ongoing uncertainty following the termination of the TACTI-004 trial, which has led to a significant loss of investor confidence.

1 analysts cover IMMP: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.